ReviewAnnual review of medicine2015
Cardiovascular disease in adult survivors of childhood cancer.
Review in Annual review of medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07712328 (A Randomized, Controlled, Open-Label Clinical Trial of Prophylactic Intraoperative Desmopressin), which is not on this map. Cited by 66 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Controlled, Open-Label Clinical Trial of Prophylactic Intraoperative Desmopressin (dDAVP) in Patients Undergoing Surgery for Complex Sellar Region Tumors
Who cites it
66 citing papers in PubMed, 4 syntheses or guidelines pooled it, 123 citations in OpenAlex.
- Anthracyclines-Induced Vascular Endothelial Dysfunction in Cancer Patients and Survivors Using Brachial Flow-Mediated Dilation (FMD) Tool: A Systematic Review and Meta-Analysis.Cardiovascular toxicology · 2025Pooled it
- A meta-analysis of risk factors for cardiovascular adverse events with anthracycline based chemotherapy in lymphoma patients.BMC cancer · 2025Pooled it
- Long-term risk of cardiovascular mortality in lymphoma survivors: A systematic review and meta-analysis.Cancer medicine · 2018Pooled it
- The prevention, detection and management of cancer treatment-induced cardiotoxicity: a meta-review.BMC cancer · 2015Pooled it
- Genetic Polymorphisms Affecting Cardiac Biomarker Concentrations in Children with Cancer: an Analysis from the "European Paediatric Oncology Off-patents Medicines Consortium" (EPOC) Trial.European journal of drug metabolism and pharmacokinetics · 2020Trial
- Trial
- Epigenome-wide analysis identifies DNA methylation mediators of treatment-related cardiometabolic risk in survivors of childhood cancer.Nature communications · 2026Article
- MitoQ reduces senescence burden in doxorubicin-treated endothelial cells by reducing mitochondrial ROS and DNA damage.American journal of physiology. Heart and circulatory physiology · 2025Article
- Timing and combinations of cardiovascular diseases in survivors of childhood, adolescent, and young adulthood cancer.Cardio-oncology (London, England) · 2025Article
- CELF4 (rs1786814) gene polymorphism and speckle-tracking Echocardiography for cardiovascular complications in childhood cancer survivors.Pediatric research · 2025Article
- SLAMF7 Restrains Pro-Inflammatory Macrophage Activation to Counteract Doxorubicin-Induced Cardiotoxicity.JACC. Basic to translational science · 2025Article
- Review
- Integration and Potential Applications of Cardiovascular Computed Tomography in Cardio-Oncology.Current cardiology reports · 2025Review
- Morbidity and mortality among children, adolescents, and young adults with cancer over six decades: a Swedish population-based cohort study (the Rebuc study).The Lancet regional health. Europe · 2024Article
- Neutrophil extracellular traps mediate cardiomyocyte ferroptosis via the Hippo-Yap pathway to exacerbate doxorubicin-induced cardiotoxicity.Cellular and molecular life sciences : CMLS · 2024Article
- Beta-blocker adjunct therapy as a prospective anti-metastatic with cardio-oncologic regulation.Clinical & experimental metastasis · 2024Review
- Incidence of Cardiovascular Complications in Pediatric Patients Treated with Anthracyclines at a Brazilian Cancer Center.Arquivos brasileiros de cardiologia · 2024Article
- Focus on Paediatric Restrictive Cardiomyopathy: Frequently Asked Questions.Diagnostics (Basel, Switzerland) · 2023Review
- UnravelingACS omega · 2023Article
- Adherence to healthy diet and risk of cardiovascular disease in adult survivors of childhood cancer in the St. Jude Lifetime Cohort: a cross-sectional study.BMC medicine · 2023Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
Abstract
Treatment advances have increased survival in children with cancer, but subclinical, progressive, irreversible, and sometimes fatal treatment-related cardiovascular effects may appear years later. Cardio-oncologists have identified promising preventive and treatment strategies. Dexrazoxane provides long-term cardioprotection from doxorubicin-associated cardiotoxicity without compromising the efficacy of anticancer treatment. Continuous infusion of doxorubicin is as effective as bolus administration in leukemia treatment, but no evidence has indicated that it provides long-term cardioprotection; continuous infusions should be eliminated from pediatric cancer treatment. Angiotensin-converting enzyme inhibitors can delay the progression of subclinical and clinical cardiotoxicity. All survivors, regardless of whether they were treated with anthracyclines or radiation, should be monitored for systemic inflammation and the risk of premature cardiovascular disease. Echocardiographic screening must be supplemented with screening for biomarkers of cardiotoxicity and perhaps by identification of genetic susceptibilities to cardiovascular diseases; optimal strategies need to be identified. The health burden related to cancer treatment will increase as this population expands and ages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.